Scott W. Mader

Mr. Mader has spent over 30 years dedicated to marketing clinically applied products. For 10 years, Scott was a product launch specialist for the Bristol-Myers Squibb Company. His marketing success with novel products such as Azactam (antibiotic), Capoten (antihypertensive, CHF), and Pravachol (metabolism) culminated with the introduction of Glucophage (type 2 diabetes), the most successful launch in BMS history at the time. In 1997, Scott led Marketing at Biosite, Inc. (La Jolla, CA) and the introduction of the novel point-of-care diagnostic Triage Meter and a series of novel biomarkers. He spearheaded the clinical strategy behind the blockbuster Triage BNP Test (Heart Failure), a biomarker that is now standard of care in acute heart failure diagnosis. In 2003 he founded CLINDEVOR 360, a strategic consultancy for biopharma, device and diagnostic products.